{"entity":{"id":"immunotherapy-response","kind":"term","name":"Immunotherapy response and its prediction","aka":["immunotherapy response","response to immunotherapy","checkpoint inhibitor response","immunotherapy responder","IO response prediction"],"tldr":"Immunotherapy response means whether a patient's cancer shrinks or stays controlled when the immune system is unleashed; predicting who will respond is one of the hardest open problems in cancer AI.","summary":"Cancer immunotherapy stimulates the immune system to treat cancer (Wikipedia). Only a minority of patients respond to checkpoint inhibitors, and the approved predictors (PD-L1 staining, mismatch repair deficiency, tumour mutational burden) are imperfect, so pathology and multimodal foundation models are trained to predict benefit from slides, sequencing and clinical data; MUSK reported such a task. Response is defined by imaging criteria at set time points, which makes the label noisy.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Cancer_immunotherapy","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cancer_immunotherapy"}],"tags":["cansim-terms"],"related":["pdl1","cancer-ai-vocabulary"],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","musk"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tmb","biomarker"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Listed in the CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme; CanSim page path /terms/immunotherapy-response."],"provenance":{"editedBy":"OnCo CanSim terms wave (Wikipedia summaries, standards and project pages, GDC and FDA pages, Europe PMC)","editedOn":"2026-09-24","note":"CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme"},"category":"Biomarkers"},"route":"/terms/immunotherapy-response/","neighbours":{"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"term":[{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"tertiary-lymphoid-structures","kind":"term","name":"Tertiary lymphoid structures (TLS)","route":"/terms/tertiary-lymphoid-structures/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"musk","kind":"technology","name":"MUSK (Stanford, vision-language pathology)","route":"/technologies/musk/"}]}}